Spermidine suppresses liver fibrosis by remodeling the communication signal between liver sinusoidal endothelial cells and hepatic stellate cells.

Hepatic fibrosis is a pivotal stage in which chronic liver disease progresses from reversible injury to decompensation. Liver sinusoidal endothelial cells (LSECs) play a regulatory role in hepatic stellate cells (HSCs) activation through paracrine signaling; therefore, maintaining the physiological phenotype of LSECs is critical for antifibrotic intervention. Spermidine (SPD) has been recognized for its antifibrotic properties; however, its impact on LSECs' function and the underlying mechanism remains largely unknown. In this study, analysis of NHANES data revealed an inverse association between dietary SPD intake and fibrosis risk. Consistently, in vivo and in vitro models demonstrated that SPD significantly ameliorated LSECs dysfunction and attenuated fibrosis progression. Through an integrative analysis incorporating proteomics, public single-cell datasets, and machine-learning prioritization, we identified LSECs-derived biglycan (BGN) as a principal target of SPD; notably, BGN overexpression diminished the capacity of SPD to restore LSECs function and facilitated HSCs activation. Mechanistically, SPD activated NRF2 to increase UBE2G2 expression, thereby enhancing UBE2G2-dependent ubiquitination and degradation of BGN. UBE2G2 knockdown reversed SPD-induced BGN downregulation, subsequently exacerbating LSECs capillarization and enhancing HSCs activation. Furthermore, Bgn overexpression in the CCl